The overall objective of the study is to determine the therapeutic effect and tolerance of
Tocizilumab in patients with moderate, severe pneumonia or critical pneumonia associated with
Coronavirus disease 2019 (COVID-19). Tocilizumab (TCZ) is an anti-human IL-6 receptor
monoclonal antibody that inhibits signal transduction by binding sIL-6R and mIL-6R. The study
has a cohort multiple Randomized Controlled Trials (cmRCT) design. Randomization will occur
prior to offering Tocilizumab administration to patients enrolled in the COVIMUNO-19 cohort.
Tocilizumab will be administered to consenting adult patients hospitalized with CORVID-19
either diagnosed with moderate or severe pneumonia requiring no mechanical ventilation or
critical pneumonia requiring mechanical ventilation. Patients who will chose not to receive
Tocilizumab will receive standard of cares. Outcomes of Tocilizumab-treated patients will be
compared with outcomes of standard of care treated patients as well as outcomes of patients
treated with other immune modulators.